Show simple item record

dc.contributor.authorHerzberg, Daniel L.
dc.contributor.authorSukumaran, Harry P.
dc.contributor.authorViscusi, Eugene
dc.description.abstractGlobally, non-steroidal anti-inflammatory drugs (NSAIDs) are highly used to treat pain. With the rise of the COVID-19 pandemic, the safety of NSAIDs use has been called into question. These concerns are worthy of review. At present, there is no compelling data showing that NSAIDs worsen the severity of COVID-19 symptoms or increase one’s likelihood of contracting the illness. For patients in pain and without symptoms that could potentially be attributed to COVID-19 (cough, fevers/chills, lethargy, myalgias, anosmia and so on), NSAIDs should continue to remain a viable option to provide analgesia to patients in need. This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.en_US
dc.subjectCoronavirus Infectionsen_US
dc.subjectInfectious Diseasesen_US
dc.subjectAnti-Inflammatory Agents, Non-Steroidalen_US
dc.titleNSAIDs for analgesia in the era of COVID-19en_US
eihealth.categoryClinical characterization and managementen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalRegional Anesthesia & Pain Medicineen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record